Treatment Overview: ADA, AACE, DCCT, UKPDS Flashcards
An A1c test measure average plasma glucose over the previous ___ to ___ months.
2-3
How often should an A1c be tested in a patient with good glycemic control?
twice yearly
How often should a patient have an A1c test done if their therapy has recently been changed or who are not meeting treatment goals?
once every quarter
What are the ADA goals for preprandial glucose and postprandial glucose?
- Preprandial: 70-130 mg/dL
- Postprandial: <180 mg/dL
What are the ADA targets for blood pressure?
<130/80 mmHg
What is the ADA targets for lipids? (LDL, triglycerides, HDL)
- LDL: <100 mg/dL
- Triglycerides: <150 mg/dL
- HDL: >40 mg/DL (men), >50 mg/dL (women)
What are the AACE goals for preprandial and postprandial glucose?
- Preprandial: <110 mg/dL
- Postprandial: <140 mg/dL
What was DCCT stand for?
Diabetes Control and Complications Trial
What patient population did the DCCT study?
type 1 patients
What did the DCCT compare?
type 1 patients who were either managed with intensive insulin therapy (3 or more injections per day) or with a more conventional regimen (1-2 insulin injections per day)
What was a key finding of the DCCT?
Any reduction in A1c is helpful in preventing or reducing the complications of type 1 diabetes.
What was the potential adverse effect(s) associated with intensive insulin therapy according to the DCCT?
- intensive therapy had a 2-3 fold greater incidence of severe hypglycemia.
- weight gain
According to the ADA, what should the treatment regimen be in every newly diagnosed type 2 patient?
lifestyle changes and metformin
What does UKPDS stand for?
United Kingdom Prospective Diabetes Study
What group of patients did UKPDS study?
type 2 patients
How many patients were in the UKPDS?
3,867
How long were patients in the UKPDS followed?
10 years
What was the purpose of the UKPDS?
to compare patients who were randomized to conventional therapy (diet alone) or intensive therapy (managment with 1 or more pharmacologic agents, including insulin)
What was the median A1c at the end of the trial for patients in the conventional arm versus the intensive arm?
7.9% for conventional, 7.0% for intensive
Compared to conventional therapy, intensive therapy reduced microvascular complications (retinopathy, nephropathy, neuropathy) by _____%.
25%
According to UKPDS, for every ____% decrease in A1c achieved there was a _____% decrease in the risk of microvascular complications.
1% decrease, 35% decrease
In UKPDS, there was a nonsignificant trend toward a reduced risk of ________________ with intensive therapy.
myocardial infarction